Savara (SVRA)
(Delayed Data from NSDQ)
$4.46 USD
-0.12 (-2.62%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
SVRA 4.46 -0.12(-2.62%)
Will SVRA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SVRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SVRA
Zacks.com featured highlights include Savara, The LGL Group, and Harte Hanks
3 Top Breakout Stocks to Add to Your Portfolio Now
SVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
After Golden Cross, Savara Inc. (SVRA)'s Technical Outlook is Bright
Other News for SVRA
Biotech Alert: Searches spiking for these stocks today
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
Savara prices ~$100M stock offering
Largest borrow rate increases among liquid names
Savara price target raised by $2 at Guggenheim, here's why